Which action should the nurse take when providing postoperative nursing care to a child after insertion of ventriculoperitone (VP) shunt?

A. Trientine: Trientine is a medication used to treat copper overload in conditions like Wilson's disease. It is not indicated for iron overdose or toxicity.

B. Dimercaprol: Dimercaprol, also known as BAL (British Anti-Lewisite), is a chelating agent used to treat heavy metal poisoning but is not primarily used for iron overload or toxicity.

C. Ferrous gluconate: Ferrous gluconate is an iron supplement used to treat iron-deficiency anemia by providing additional iron to the body. It is not appropriate for treating iron overdose, as it would worsen the situation.

D. Deferoxamine.

Iron overdose, also known as iron toxicity, can lead to serious complications, including cardiac dysrhythmias. Deferoxamine is a chelating agent used to remove excess iron from the body in cases of iron overload or toxicity, such as in patients with conditions like sickle cell anemia who require frequent blood transfusions. It binds to excess iron and helps excrete it from the body, reducing the risk of iron-related complications, including cardiac issues.

A. Bone marrow transplantation.

Severe aplastic anemia is a condition characterized by a significant reduction in the number of blood cells produced by the bone marrow. The primary treatment for severe aplastic anemia is a bone marrow transplantation, also known as a stem cell transplant. This procedure involves replacing the patient's dysfunctional bone marrow with healthy bone marrow or stem cells from a suitable donor. This is done to restore normal blood cell production.

Option B (Exchange transfusion) is not the primary treatment for severe aplastic anemia but may be used in certain cases to manage complications or specific symptoms.

Option C (Liver transplantation) is not a treatment for severe aplastic anemia, as this condition primarily affects the bone marrow and blood cell production.

Option D (Administration of intravenous immunoglobulin) is not the primary treatment for severe aplastic anemia but may be used in some cases to manage complications, such as infections. However, it does not address the underlying cause of the disease, which is the failure of the bone marrow to produce enough blood cells.